Field Medical

About Field Medical

Founded in 2022 by Dr. Steven Mickelsen, a practicing electrophysiologist and a key figure in pulsed field ablation (PFA), Field Medical, Inc. is a clinical-stage medical device company targeting the unmet needs in cardiac arrhythmia treatment. Dr. Mickelsen, who previously founded Farapulse (acquired by Boston Scientific), brings deep domain expertise to this venture, having pioneered advancements in PFA technology. His journey from a professional musician to a leading medical device inventor underscores a career dedicated to enhancing patient care through tangible innovation.

Field Medical is focused on developing the next generation of PFA technology to treat a wide spectrum of cardiac arrhythmias, with an initial focus on ventricular tachycardia (VT), a significantly underserved segment in electrophysiology. The company's business model centers on the development and future commercialization of its core product, the FieldForce™ Ablation System, to hospitals and cardiac care centers. This system utilizes a non-thermal energy source, delivering micro-bursts of energy via a catheter to disrupt problematic heart cells without the heat or cold signatures that are drawbacks of current ablation methods.

The FieldForce™ Ablation System is an investigational device featuring a purpose-built, contact-force focal PFA catheter. Its proprietary FieldBending™ technology is designed to concentrate the therapeutic electrical field, enabling rapid, precise, and transmural lesion creation while minimizing impact on surrounding tissues. This approach aims to provide a safer and more effective treatment for complex arrhythmias like VT. The company has received significant validation, including an FDA Breakthrough Device Designation and inclusion in the FDA's TAP Pilot Program in 2024. The company has successfully raised $75 million in funding through Series A and B rounds to support pivotal trials, such as the VERITAS trial for VT, and to scale up for commercial readiness.